1992 Epilepsy Advisory Board, Abbott Laboratories

1993 - 1995 Information Systems Physician Advisory Group (ISPAG), Memorial Medical Center

1996 - present Faculty and Advisory Board Member, J. Kiffin Penry Epilepsy MiniFellowship, Bowman-Gray School of Medicine, Winston-Salem, NC.

1996- 1999 Continuing Education Committee, American Epilepsy Society

1997 - present Ad hoc committee on Clinical Research, American Association of Medical Colleges

1997 Ad hoc committee on Committee Structure and Process, American Society of Clinical Pharmacology and Therapeutics

1998- present Constitution and Bylaws Committee, Vice-chair/chair designate (1999-2001), American Society for Clinical Pharmacology and Therapeutics

1999 - present Education Committee, Vice-chair /chair designate (2000-2003), American Society for Clinical Pharmacology and Therapeutics

2000 - present Scientific Advisory Board, Citizens United for Research in Epilepsy (CURE)

Honors and Awards

1975 Phi Eta Sigma Honor Society

1985-1986 USPHS Postdoctoral Fellow (5-T-32-NS07205-04)

1986-1987 Seay Neuropharmacology Fellowship

1989 American Epilepsy Society, Young Investigator Travel Award

1989 Moderator, Experimental Seizure Scientific Session, American Epilepsy Society; Boston MA.

1991 Special Recognition Award, Epilepsy Assn. of Lincoln Land

2001 Kingston's Who's Who - Life member #186671

CLINICAL AND TEACHING EXPERIENCE

1986 - 1987 Attending in Movement Disorders and Epilepsy Clinic,

Washington University

Department of Neurology

St. Louis, Missouri

1986 - 1987 Special topics instructor in Pharmacology Course

Washington University School of Medicine

St. Louis, Missouri

1987 - present Faculty

Sophomore Medical Student Pharmacology lecture series and

Graduate School Neuropharmacology course,

Southern Illinois University School of Medicine

Springfield, Illinois

1989 - present Course Director

Clinical Neurophysiology/EEG Course

and EEG clinical rotations

Neurology Residency

Southern Illinois University School of Medicine

1991 - 1994 Faculty/preceptor, NIH High School Minority Research

Training Program (1991, 1992, 1994) (Peter Pacha, Heidi

Angeles, Danette Gillespie)

1993 Course Director,The Network Perspective in Epilepsy:

Directions for Research and Therapy. Satellite Symposium,

American Epilepsy Society Annual Meeting, 1993.

1995- Preceptor, Illinois Governmental Internship Program

Jennifer Hott -1995

Carrie Ricketts - 1996

Lacie McDaniel - 1996

1995 Course Director, SIU Annual Neurology Symposium

Epilepsy and Neurotherapeutics. Springfield, IL

1994 Course Director, Vagus Nerve Stimulation: Mechanisms and

Clinical Aspects. Satellite Symposium at the 21st International

Epilepsy Congress, Sydney, Australia.

1995 Course Director, Role of Integrative Research in Epilepsy,

Roundtable, American Epilepsy Society Annual Meeting,

San Francisco, CA

1997-1999 Graduate school committee - Kevin B. Clark, Ph.D.

Southern IL University

1998 - present Course Director, Advanced Therapeutics (senior medical

student curriculum in clinical pharmacology)

Southern IL University, Springfield, IL

1999 Graduate school committee (M.A.) - Tina Holder, M.A.

University of IL at Springfield

1999 - 2004 Graduate school committee (Ph.D.) - Krystal Vonck, M.D.

University of Ghent, Ghent Belgium

1999 Course director and moderator - Epilepsy MiniFellowship Symposium XII, American Epilepsy Society, Orlando Florida

2000 - present Preceptor for Post-doctorate studies - Olivier Darbin, Ph.D.

2000 Course Director: Potpourri: A better understanding of antiepileptic drugs and how they function. Satellite meeting at American Epilepsy Society Annual Meeting, Los Angeles, CA

WEBMASTER

1997- present SIU Department of Neurology

http://www.siumed.edu/neuro

SIU Center for Epilepsy

http://www.siumed.edu/neuro/epilepsy.html

1998- present J. Kiffin Penry MiniFellowship Programs

http://www.minifellow.net

1999- present Citizens United for Research in Epilepsy (CURE)

http://www.siumed.edu/neuro/cure

JOURNAL EDITORIAL BOARD

1999 - present Clinical decision making in the management of epilepsy. (CME journal sponsored by the American Epilepsy Society)

GRANTS

Laboratory Research Funding - Principal Investigator

SIU-CRC (23-89): Functional Anatomy of Progressive Seizure Severity and Electroencephalographic Spike-Wave Activity Following Repeated Audiogenic Seizures in the Genetically Epilepsy Prone Rat (GEPR). $4898; 7/1/88-6/30/89.

SIU-CRC (7-90): Functional Anatomy of Progressive Seizure Severity and Electroencephalographic Spike-Wave Activity Following Repeated Audiogenic Seizures in the Genetically Epilepsy Prone Rat (GEPR). $5000; 7/1/89-6/30/90.

Epilepsy Foundation of America: Studies on GABA in Progressive Seizure Severity and Cortical Epileptiform Activity in the Genetically Epilepsy-Prone Rat; $24,829; 4/1/90 - 3/31/91.

SIU-CRC (26-91): Studies on Glycine in Audiogenic Seizures in the Genetically Epilepsy-Prone Rat (GEPR-9). $2500; 7/1/90-6/30/91

SIU-CRC (17-92): Studies on Glycine in Audiogenic Seizures in the Genetically Epilepsy-Prone Rat (GEPR-9). $3400; 7/1/91-6/30/92

SIU-CRC (23-93): Studies on c-fos Expression in the Forebrain During Audiogenic Seizure Repetition. $4325; 7/1/92-6/30/93.

SIU Program Project: Mechanisms of Seizure Susceptibility - Reductions in GABA Efficacy in the Genetically Epilepsy-Prone Rat. $42,768; 12/1/92-11/30/94.

Cyberonics, Inc: Functional Anatomy of Vagus Nerve Stimulation. $25,000. 7/1/93 - 6/30/94.

SIU Program Project: "Studies on GABAA receptor function during aging," $37,509; 3/94-2/96.

NIH/NINDS (R15 NS34142): Antiepileptic Mechanisms of Vagus Nerve Stimulation. $104,077; 6/1/95-5/31/98.

Cyberonics, Inc: "Studies on the role of brain monoamines in the anticonvulsant effect of vagus nerve stimulation (VNS)." (co-principle investigator with R. Browning) $9094; 7/1/95-6/30/97.

SIU Central Research Committee: "Effects of alternative stimulation parameters in experimentally induced seizures. Award amount: $9,800. Project period 7/1/98 - 6/30/99.

Cyberonics, Inc. "An investigation of the capacity of vagus nerve stimulation to alter the course of recovery of function from brain damage in laboratory rats." (Douglas Smith and Robert A. Jenson, co-principal investigators) $40,000. 7/14/98-7/13/00.

SIU Central Research Committee : "Characterization of seizure-evoked arrhythmia." $9,992. 7/1/01-6/30/02.

Clinical Research Funding - Principal Investigator

McNeil Pharmaceutical: Double-Blind Parallel Comparison of Three Doses of Topiramate (Low to Mid Range) and Placebo in Refractory Partial Epilepsy (YD). $129,108; 1988-1990.

McNeil Pharmaceutical : Long Term Effectiveness of Topiramate on Refractory Partial Seizures Topiramate (YK-P and YKP). $113,722; 4/89 - 1995.

McNeil Pharmaceutical: A Double-blind, Placebo-Controlled, Parallel, Efficacy and Safety Study of Topiramate in Patients with Partial Epilepsy followed by Topiramate Single Therapy as Accomplished by the Reduction of concomitant Tegretol (or Dilantin) (YF and YG). $145,363; 4/89 - 1992.

Parke-Davis Pharmaceutical: Gabapentin: An Open-Label Multicenter Study of the Safety and Efficacy of Gabapentin as Monotherapy or Add-on Therapy in the Long-term Treatment of Epileptic Seizures. $47,739; 5/89 - 1993.

Cyberonics, Inc: Vagus Nerve Stimulation for Intractable Partial Epilepsy. $84,586; 11/90-1992.

Abbott Laboratories: Safety of Intravenous Valproate. $6,951; 1992.

Abbott Laboratories: Safety and Efficacy of B.I.D. and Q.I.D. Dosing with Tiagabine HCl Versus Placebo as Adjunctive treatment for Partial Seizures. $ 148,850; 7/1/92-1995.

Parke-Davis Pharmaceutical: Conversion from Marketed Antiepileptic Drug Therapy to Gabapentin (CI-945) Monotherapy in Patients with Complex Partial or Secondarily Generalized Seizures: A Double-Blind, Dose-Controlled , Multicenter Study. (945-082) $78,000; 5/93 - 1995.

Dainippon Pharmaceuticals: Baseline Controlled Safety and Efficacy of Zonisamide in the Treatment of Seizures in Medically Refractory Patients (810-920). $76,750; 8/93 - 1994.

Dainippon Pharmaceuticals: Long-term Safety and Efficacy Evaluation of Zonisamide in the Treatment of Seizures in Medically Refractory Patients and Efficacy Evaluation of Zonisamide Monotherapy (810-921). $153,800; 8/93 - 1999.

Schwabe Pharmaceuticals: Losigamone study. $77,925; 8/94-7/96.

Cyberonics, Inc.: E05: Assessment of vagus nerve stimulation (VNS) for adjunctive treatment of epilepsy patients who have refractory partial onset seizures with alteration of consciousness. $189,875; 4/95-3/97.

Cyberonics, Inc.: XE5: Open-Label Treatment of Refractory Partial Onset Seizures Using Vagus Nerve Stimulation. Principal Investigator - Dean K. Naritoku, M.D. ; $30,000 11/95 - 8/97

Glaxo Wellcome Inc.: Protocol SCAA4001: A Double-Blind, Double-Dummy, Parallel-Group Comparison of Lamotrigine and Divalproex Sodium Monotherapy in Patients with Generalized Seizures. Principal Investigator - Dean K. Naritoku, MD; $52,416; 10/96 - 1999

Ortho-McNeil Pharmaceutical: Protocol CAPSS-027: A Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Efficacy of Topamax(r)(Topiramate) Compared to Valproate as Add-on Therapy to Carbamazepine with Special Emphasis on Cognitive Function in Subjects with Partial-Onset Seizures. Principal Investigator - Dean K. Naritoku, MD.; $49,600; 3/97- 1999

Warner-Lambert/Parke-Davis: "Study in patients with partial seizures" (pregabalin). Project period: 4/9/98-4/8/99; award amount: $62,487. This is a randomized, double-blind placebo controlled phase III trial that assesses the efficacy of pregabalin as an add-on therapy.

Warner-Lambert/Parke-Davis: "Study to determine the efficacy in patients with partial seizures": Project period: 4/9/98-4/8/99; award amount $57,050. This is an open-label extension study for patients exiting the blinded phase of the above pregabalin study.

Abbott Laboratories: The Safety and Tolerance of Intravenous Depacon at an

Infusion Rate up to 3.0 mg/kg/min in Subjects with Epilepsy. Award amount: $72,609.

Abbott Laboratories: Comparison of the bioavailability of a depakote extended-release formulation relative to the depakote delayed-release tablet formulation in adult patients with epilepsy on the depakote delayed-release tablet formulation and an enzyme-inducing antiepileptic drug. Award amount: $117,900 (9/1/01-8/30/02)

Elan Pharmaceuticals: A double-blind, randomized, multicenter, parallel group study to establish dose-response, safety, and efficacy of Zonegran‚ (zonisamide) as monotherapy in patients with newly diagnosed epilepsy. $60,034 (9/1/01-8/30/02)

Funding as co-investigator

NIH (R01 NS 21281): Neurotransmitter Seizure Mechanisms; Principal Investigator: Carl L. Faingold; $211,851; 9/1/88-8/31/91

Wallace Laboratories: Monotherapy Comparison of Felbamate and Valproate in Partial Seizures. Principal Investigator - M. Steven Evans; $ 84,586.80; 12/89 - 1990.

Wallace Laboratories: A Multicenter, Open-Label, Long-Term Evaluation of the Safety of Felbamate in Subjects with Epilepsy. Principal Investigator - M. Steven Evans; $ 9733; 12/89 - 1993.

Wallace Laboratories: Open-Label, Follow-On, Long-Term Felbamate Therapy in Adult Subjects. Principal Investigator - M. Steve Evans; $36,113; 12/89 - 1993.

NIAAA (AA08591): Neuronal and Neurotransmitter Actions of Ethanol; Principal Investigator Carl L. Faingold; $260,329; 2/1/92- 1/31/95.

NIH (R01 NS 21281): Neurotransmitter Seizure Mechanisms; Principal Investigator: Carl L. Faingold; $311,040; 4/1/92-3/31/95.

Cyberonics: "Studies on the enhancement of memory storage processed by vagus nerve stimulation (VNS)." Principle investigators: R. Jensen; $16,659; 7/1/95-6/30/95.

U.S. PATENT AWARD

Naritoku DK, Jensen RA, Browning RA, Clark KA, Smith D and Terry RS, Jr. Methods of treating traumatic brain injury by vagus nerve stimulation. U.S. Patent #6,104,956

PUBLICATIONS

Original Research Articles

1. Naritoku DK, Levine JA, Covey D and Ferrendelli JA. Effects of anticonvulsant gamma-butyrolactones and thiobutyrolactones on GABA-dependent chloride uptake, Biochem. Pharmacol., 1987; 36:797-800.

2. Holland KD, Naritoku DK, McKeon AC, Ferrendelli JA and Covey DF: Convulsant and anticonvulsant cyclopentanones and cyclohexanones. Mol. Pharmacol. 1990; 37:98-103.

3. Naritoku DK, Mecozzi LB, Stryker MT, and Faingold CL. Repetition of audiogenic seizures in genetically epilepsy-prone rats induces cortical epileptiform activity and additional seizure behaviors. Exp. Neurol. 1992;115:317-324.

4. Naritoku DK, Morales A, Pencek TL and Winkler D. Chronic Vagus Nerve Stimulation Increases the Latency of the Thalamocortical Somatosensory Evoked Potential. Pacing and Clin. Elecrophysiol. 1992; 15 (II): 1572-1578.

5. Faingold CL, Naritoku DK, Copley CA, Randall MR, Riaz A, Boersma-Anderson CA, and Arneric SP. Glutamate in the Inferior Colliculus Plays a Critical Role in Audiogenic Seizure Initiation. Epilepsy Res. 1992; 13:95-105.

6. Matsuoka Y, Rakonczay A, Giacobini E, Naritoku D. L-Beta-methylamino-alanine-induced behavioral changes in rat. Pharmacol. Biochem. Behav., 1993; 44:727-734.

7. Faingold CL, Randall ME, Naritoku DK and Boersma-Anderson, CA. Non-Competitive and Competitive NMDA Antagonists Exert Anticonvulsant Effects by Actions on Different Sites Within the Neuronal Network for Audiogenic Seizures Exp. Neurol., 1993, 119:198-204.

8. Summers, K.L., Cuadra, G., Naritoku, D. and Giacobini, E. Effects of Nicotine on Levels of Acetylcholine and Biogenic Amines in Rat Cortex. Drug Devel. Res., 1994, 31:108-119.

9. Naritoku DK, Terry WJ, and Helfert, RH. Regional induction of fos immunoreactivity in the brain by anticonvulsant stimulation of the vagus nerve. Epilepsy Res., 1995, 22:53-62.

10. Ramsay R.E., Augustinsson L.E., Naritoku D.K., Willis J.K., Treig T., Wernicke J.F. and First International Vagal Stimulation Study Group. Vagal Stimulation as Treatment for Partial Epilepsy: 2. Clinical and Pharmacological Correlates of Efficacy. Epilepsia , 1994, 35:627-636.

11. Patel J and Naritoku, DK. Gabapentin for the treatment of hemifacial spasm. Clin. Neuropharmacol., 1996. 19:185-188.

12. Evans, M.S., Naritoku, D.K., Ghobrial, M., Couch, J.R. Dihydroergotamine (DHE)-induced stroke in a patient with saggital sinus thrombosis. Clin. Neuropharmacol., 1996, 19:177-184.

13. Takaya M, Terry WJ and Naritoku DK. Vagus nerve stimulation induces a sustained anticonvulsant effect. Epilepsia, 1996, 37:1111-1116.

14. Campbell KCM, Naritoku DK, Evans MS, Hughes LF and Rybak LP. Is valproic acid ototoxic? Am. J. Audiology, 1996, 5:7-10.

15. Handforth A, DeGiorgio CM, Schachter SC, Uthman BM, Naritoku DK, Tecoma ES, Henry TR, Collins SD, Vaughn BV, Gilmartin RC, Labar DR, Morris GL, Salinsky MC, Osorio I, Ristanovic, Labiner DM, Jones JC, Murphy JV, Ney GC and Wheeless JW. Vagus nerve stimulation therapy for partial onset seizures. Neurology, 1998. 51:48-55.

16. Clark KB, Smith DC, Hassert DL, Browning RA, Naritoku DK and Jensen RA. Post-training electrical stimulation of vagal afferents with concomitant vagal efferent inactivation enhances memory storage processes in the rat. Neurobiol. Learn. Mem. 1998, 70:364-373.

17. Clark KB, Naritoku DK, Smith DC, Browning RA and Jensen RA. Enhanced recognition memory following vagus nerve stimulation in human subjects. Nature Neurosci., 1999, 2:94-98.

18. Naritoku DK and Mueed S. Intravenous loading of valproate for epilepsy. Clin. Neuropharmacol.,, 1999, 2:102-106.

19. Espinosa J, Aiello MT and Naritoku DK. Revision and removal of stimulation electrodes following long-term therapy with the vagus nerve stimulator. Surgical Neurol. , 1999, 51:659-664.

20. Caspary DM, Holder-Shanklin TH, Millbrandt J, McKernan RM and Naritoku DK. Changes in GABAA receptor composition and function in the rat inferior colliculus as a consequence of aging. Neurosci., 1999, 93: 307-302.

21. Sirven JI, Sperling M, Naritoku D, Schachter S, Labar D, Holmes M, Wilensky A, Cibula J, Labiner DM, Bergen D, Nadkarni M, Harvey J, Dasheiff R, Morris GL, Ristanovic R, Richards B, Sanchez J. Efficacy and tolerability of vagus nerve stimulation therapy for epilepsy in older adults. Neurology, 2000, 54:1179-82.

22. Naritoku DK and Sinha S. Prolongation of midazolam half-life following sustained infusion for status epilepticus. Neurology, 2000, 54:1366-8.

23. Sinha S, and Naritoku DK. Intravenous valproate is well tolerated in hemodynamically unstable patients with status epilepticus. Neurology, 2000, 55:722-4.

24. DeGiorgio CM, Schachter SC, Handforth A, Salinsky M, Thompson J, Uthman B, Reed R, Collins S, Tecoma E, Morris GL, Vaughn B, Naritoku DK, Henry T, Labar D, Gilmartin R, Labiner D, Osorio I, Ristanovic R, Jones J, Murphy J, Ney G, Wheless J, Lewis P, Heck C. Prospective long-term study of vagus nerve stimulation for the treatment of refractory seizures. Epilepsia, 2000, 41:1195-1200.

25. DeGiorgio CM, Thompson J, LewisP, Arrambide S, Naritoku D, Handforth A, Labar D, Mullin P, Heck C, and the VNS U.S. Study Group. Vagus nerve stimulation: Analysis of device parameters in 154 patients during the long-term XE5 study. Epilepsia, 2001, 42: 1017-1020.

26. Feng H-J, Naritoku DK, Randall ME, Faingold CL. Modulation of audiogenically kindled seizures by GABA-related mechanisms in the amygdala, Exp. Neurol., 2001 (in press).

Articles Submitted and Pending Review

1. Kalkanis JG, Krishna MD, Espinosa JA, Naritoku DK. Self-inflicted vocal cord paralysis in two patients with vagus nerve stimulators. Submitted to J. Neurosurg.

2. Ramsay RE, Cantrell D, Collins SD, Walch JK, Naritoku DK, Cloyd JC, Sommerville KW, and the Depacon Rapid Infusion Study Group. Safety and tolerance of rapidly infused Depacon(r): A randomized trial in subjects with epilepsy. Submitted to Neurology.

3. Espinosa JA, Verma-Ahuja S, Naritoku DK, Farris C, Evans MS. Human vagus nerve compound action potentials recorded during implantation of a vagus nerve stimulator. Submitted to J. Clin. Neurophysiol.

Review Articles

1. Dailey JW and Naritoku DK. Antidepressants and seizures: clinical anecdotes overshadow neuroscience. Biochem. Pharmacol.,1997, 52:1323-1329.

2. Hernandez TD and Naritoku DK. Traumatic brain injury and neurorehabilitation: a re-appraisal. Neurology, 1997, 48:803-806.

Book Chapters

1. Faingold CL and Naritoku DK. Genetically epilepsy-prone rat: neuronal networks and amino acid transmitters. In: Drugs for Control of Epilepsy: Actions on Neuronal Networks Involved in Seizure Disorders, Faingold CL and Fromm GL (eds). Boca Raton, Florida: CRC Press, 1991, pp. 277-308.

2. Naritoku DK and Hernandez, TD. Posttraumatic Epilepsy and Neurorehabilitation. In: Traumatic Brain Injury Rehabilitation:(Ashley MJ and Krych DK eds). Boca Raton, Florida: CRC Press, 1995.

Publications Resulting From Multicenter Studies

1. Ben-Menachem E, Hufnagel, Wilder, Stefan, Mirza and First International Vagal Stimulation Study Group. Vagal Stimulation as Treatment for Partial Epilepsy: 1. Effect on Seizures in a Controlled Study. Epilepsia, 1994, 616-626.

2. George R, Salinsky M, Kuzniecky R, Rosenfeld W, Bergen D, Tarver WB, Wernicke JFand First International Vagus Nerve Stimulation Study Group. Vagus nerve stimulation for treatment of partial seizures: 3. Long-term follow-up on first 67 patients exiting a controlled study. Epilepsia, 1994, 35(3):637-43.

3. Salinski, Manon, Kuzniecki, Rosenfeld and First International Vagal Stimulation Study Group. Vagal Stimulation as Treatment for Partial Epilepsy: 4. Long-Term Effects and Quality of Life. Epilepsia, in press.

4. The vagus nerve stimulation study group. A randomized controlled trial of chronic vagus nerve stimulation for treatment of medically intractable seizures. Neurol., 1995, 45:224-230.

5. Faught E, Wilder BJ, Ramsay RE, Reife RA, Kramer LD, Pledger GW, Karim RM and Topiramate YD Study Group. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology. 46(6):1684-90.

6. Devinsky O, Leppik I, Willmore LJ, Pellock JM, Dean C, Gates J, Ramsay RE. Safety of intravenous valproate. Ann Neurol., 1995, 38(4):670-4.

CME publications

1. Naritoku DK. Acute and chronic side effects of antiepileptic drugs in adults. In: Antiepileptic drugs: Drug interactions and adverse effects, J.M. Pellock (ed), Deerfield IL, Discovery International, 1995, pp. 12-19. (CME publication)

2. Naritoku DK. The use of anticonvulsants for the treatment of epilepsy, migraine and bipolar disorder: Epilepsy. In: Current Pharmacy Topics: A continuing education program for pharmacists. Champaign IL: Grotelueschen Associates, 1995, pp. 4-12. (CME publication)

3. Naritoku DK. Mechanisms of antiepileptic vagus nerve stimulation. In: International Medical Forum 102 (P. Chauvel, ed). Oxford UK: Blackwell Science, 1998

4. Ramsay RE and Naritoku DK. Treatments of choice for tonic-clonic seizures. Rancho Mirage CA, Annenberg Center for Health Sciences, 1998. (CME publication)

5. Naritoku DK. Use of intravenous valproate in a patient experiencing breakthrough seizures. Epilepsy: Case-based self-study for practicing neurologists., Medical College of Virginia, 1998, 1:12-13.

6. Naritoku DK. Intravenous therapies for seizures. Epilepsy MiniFellowship Lecture Series. J. Kiffin Penry MiniFellowship Program, 1998.

7. Naritoku DK and Sinha S. Status epilepticus in a patient with "Do not resuscitate" (DNR) orders. Epilepsy: Case-based self-study for practicing neurologists., Medical College of Virginia, 1999, 2:4-5.

8. French J, Naritoku DK, Ramsay RE and Tatum WO (eds) Best practices in epilepsy - DIalogues in Neurotherapeutics. Health Learning Systems/University of Kentucky Continuing Education Office, 2001.

9. Naritoku DK. Outcome of status epilepticus treated with intravenous valproate. Advanced Studies in Medicine, Johns Hopkins Univerisity, 2001 in press.

10. Naritoku DK (editor), Ramsay RE, Wheless JW. Use of intravenous antiepileptic drugs in emergency situations. Dannemiller Memorial Educational Foundation 2001 in press.

11. Naritoku DK (editor) A better understanding of antiepileptic drugs and how they function. Access Medical Group, in press.

Abstracts

1. Naritoku DK, Levine JA, Covey D and Ferrendelli JA. Comparative Anticonvulsant Effects of Ethosuximide, Valproic Acid, Gamma Butyrolactones and Thiobutyrolactones, Soc. Neurosci. Abstr., 1986.

2. Naritoku DK, McKeon AC, Levine JA, Covey DF and Ferrendelli JA. Structure-Activity Relationships of Alpha-alkyl-submitted Gamma-butyrolactones and Thiobutyrolactones. Epilepsia 1987.

3. Naritoku DK, Mecozzi LB and Faingold CL. Repeated Audiogenic Seizures (AGS) Produce Epileptiform Cortical Activity and Increased Seizure Severity in Genetically Epilepsy-Prone Rats (GEPR-9s). Generalized Epilepsy Symposium Abstr., 1988.

4. Naritoku DK, Stryker MT, Mecozzi LB, Copley CA and Faingold CL. Gabapentin Reduces the Severity of Audiogenic Seizures (AGS) in the Genetically Epilepsy-Prone Rats (GEPR-9), Epilepsia., 1988.

5. Naritoku DK, Mecozzi LB and Faingold CL. Effects of Repeated Audiogenic Seizures (AGS) on Seizure Severity and EEG in Two Substrains of the Genetically Epilepsy-Prone Rat (GEPRs), Soc. Neurosci. Abstr., 1988;14:252.

6. Naritoku DK, Mecozzi LB, Randall ME and Faingold CL. Infusions of GABA Agonists or 2-APH into Amygdala (AMY) or Medical Geniculate (MGB) Reversibly Reduce Seizure Duration and Clonus after Repeated Audiogenic Seizures (AGS) in the Genetically Epilepsy-Prone Rat (GEPR-9). Soc. Neurosci. Abstr. 1989;15:46.

7. Naritoku D.K., Randall M.E., and Faingold C.L. Microinfusions of GABA Agonists and 2-APH into Amygdala Reduce Seizure Duration and Clonus in Repeated Audiogenic Seizures (AGS) in the Genetically Epilepsy-Prone Rat (GEPR-9). Epilepsia, 30:698, 1989.

8. Naritoku DK, Mecozzi LB, Randall ME and Faingold CL. Effects of glycine and milacemide, a glycine prodrug, on audiogenic seizures in the genetically epilepsy-prone rat (GEPR-9). Soc. Neurosci. Abstr. 1990;16:785.

9. Naritoku DK, Matsuoka Y, Rakonczay Z and Giacobini E. Intraventricular infusions on L-ß-Methylamino-alanine (L-BMAA) result in convulsive seizures and cortical epileptiform discharges. Epilepsia 1990;31:608.

10. Naritoku DK, Morales A and Winkler D. Chronic Vagus Nerve Stimulation Prolongs the Latency of the Thalamocortical (N20) Response of Somatosensory Evoked Potentials. Epilepsia., 32(S3):85-86, 1991.

11. Naritoku DK, Campbell C, Evans, MS and Hughes L. Does valproate affect hearing? Epilepsia, 1992

12. Naritoku DK, Willis J, Monon-Espaillat, R, and NCP study group. Patient Activated "Therapeutic Bursts" of Stimulation Delivered Via the Vagus Nerve. Epilepsia, 33 (S3):109, 1992.

13. Ramsay E, Ben-Menachem E, Upton A, Naritoku D, Ristanovic R and NCP Study Group. One year follow-up of 29 patients with refractory epilepsy treated in a controlled study of vagal stimulation. Epilepsia, 33 (S3):102, 1992.

14. Naritoku DK, Campbell K, Evans MS, Hughes L. Does Valproate Administration Alter Auditory Threshold? Epilepsia 1992; 33(S3):109-110.

15. Naritoku D, Willis J, Manon-Espillat R, NCP Study Group. Patient-Activated "Therapeutic Bursts" of Stimulation Delivered via the Vagus Nerve. Epilepsia 1992; 33(S3):102.

16. Campbell KCM, Evans MS, Naritoku DK, Hughes LF. Is valproic acid ototoxic? ARO Abstr 1993; 144.

17. Uthman BM, Ben-Menachem E, Ramsey RE, Naritoku D, Hufnagel A. 18-month follow-up of 32 epilepsy patients receiving vagus nerve stimulation (VNS). Neurology, 1993; 43:A161.

18. Uthman BM, Ramsay E, Naritoku DK, Manon-Espaillat R, Sonnen AEH. One year efficacy results of therapeutic vagus nerve stimulation (VNS) in 61 epilepsy patients. Epilepsia, 34(S2): 192-193. 1993.

19. Naritoku DK, Beckman SL, Evans MS. GABAA receptor efficacy is reduced in the cerebral cortex of the genetically epilepsy-prone rat (GEPR-9). Soc. Neurosci Abstr, 1993.

20. Naritoku DK, Terry WJ, Faingold CL, Helfert RH. Forebrain fos expression during audiogenic seizure repetition in the genetically epilepsy-prone rat (GEPR-9). Epilepsia 1993, 34(S6):22.

21. Chakravarty DN, Faingold CL, Terry WJ, and Naritoku DK. Audiogenic seizures in the genetically epilepsy-prone rat induce c-fos proto-oncogene expression in the inferior colliculus and periaqueductal gray. Soc. Neurosci Abstr, 1993.

22. Naritoku DK and Beckman SL. Reduction of GABAA receptor efficacy in the genetically epilepsy-prone rat: differential response to modulation by a cyclic AMP analog. Epilepsia, 34(S6):76.

23. Terry WJ and Naritoku DK. Patterns of fos production in the forebrain following intermittent vagus nerve stimulation. Epilepsia, 34(S6):8-9, 1993.

24. Uthman, B., Wilder, B.J., Ramsay, E., Naritoku, D. Follow-up of 53 refractory epilepsy patients receiving vagus nerve stimulation for 18 months. Epilepsia, 34(S6):29.

25. Uthman BM, Wilder BJ, Ramsay E, Ben-Menachem E, Naritoku D. Long term follow-up of 70 refractory partial epilepsy patients receiving vagus nerve stimulation. Neurology, 43:A161.

26. Naritoku DK, Terry WJ and Takaya M. Intermittent vagus nerve stimulation activates brainstem noradrenergic nuclei. Epilepsia, 1994.

27. Naritoku, D.K., and the Vagus Nerve Stimulation Study Group. Vagus nerve stimulation: continuation rates as a measure of therapeutic outcome - results from four studies. Epilepsia, 1996

28. Clark, K.B., Smith, D.C., Hassert, D.L., Browning, R.B., Naritoku, D.K., and Jensen, R.A. Posttraining electrical stimulation of vagal afferents with concomitant efferent inactivation enhances retention performance in the rat. Soc. Neurosci. Abstr, 1996.

29. Naritoku DK, Mikels JA. Vagus nerve stimulation (VNS) attenuates electrically kindled seizures. Epilepsia 1996; 37(S5):75.

30. Rodgers-Neame NT, Aiello MT, Naritoku DK. Smoking is related to unpleasant laryngeal symptoms in persons receiving vagus nerve stimulation for seizure control. Epilepsia 1996; 37(S5):S176.

31. Terry WJ, Takaya M, Naritoku DK. Regional changes in brain glucose metabolism in rats following anticonvulsant stimulation of the vagus nerve. Epilepsia 1996; 37(S5):117.

32. Naritoku DK and Mikels JA. Vagus nerve stimulation (VNS) is antiepileptogenic in the electrical kindling model. Epilepsia 1997; 38 (S3):3.

33. Sirven JI, Bergen DC, Cibula JE, Dahieff RM, Harvey JH, Holmes MD, Labar DR, Labiner DM, Morris GL, Nadkarni MA, Naritoku DK, O'Donovan C, Ojemann LM, Richards BA, Ristanovic RK, Sanchez JD, Scales DF, Schachter SC, Wilensky AJ and Sperling MR. Vagus nerve stimulation of epilepsy in adults 50 years and older: a multicenter study. Neurology 1999; 6(S2):A108-109.

34. Faingold CL, Naritoku DK, Randall ME. The role of inhibitory and excitatory glycine receptors in modulation of audiogenic seizures in the inferior colliculus (IC). Epilepsia 1999: 40(S7): 39.

35. Naritoku DK, Smith MC, Penry MD. Intensive training of primary care physicians in epilepsy: Result study. Epilepsia 1999: 40(S7): 232.

36. Sinha S, Naritoku DK. Prolongation of midazolam half-life following sustained infusion for status epilepticus. Neurology 2000, 54(S3): A307.

37. Raisinghani M, D. Casebeer D, Naritoku D, Faingold C. Modulation of postictal depression: role of opioid receptor subtypes. Soc. Neurosci. Abstr 2000.

38. Cantrell DT, Ramsay ER, Collins SD, Walch JK, Gu Y, Deaton R, Naritoku DK, Gates JR, Kuzniecky RI, Morris GL, Cloyd JC, Raroque H. Rapid infusions of Depacon are safe and well tolerated. Epilepsia 2000; 41(S7): 253.

39. Naritoku DK, Sinha S. Outcome of staus epilepticus treated with intravenous valproate. Neurology 2001 (S3): A235-236.

40. Darbin OE, Casebeer DJ, Naritoku DK. Cardiac arrhythmia occurs during the immediate postictal state following n=maximal electroshock (MES) in freely moving rats. Soc. Neurosci. Abstr. 2001 in press.

41. Darbin OE, Casebeer DJ, Naritoku DK. Cardiac arrhythmia associated with maximal electroshock (MES)-induced seiuzres are most influenced by parasympathetic activity. Epilepsia 2001 in press.

42. Brozman B, Tatum WO, Ferreira JA, Slater JD, Naritoku DK, Gallo BV, McJilton JS, Ramsay RE. Vagal nerve stimulation: efficacy of standard versus rapid cycling. Epilepsia 2001 in press.

43. Dedeurwaerdere S, Vonck K, D'have M, Naritoku D, Grisar T, Marescaux C. Vagus nerve stimulation in GAERS: results of a pilot study. Epilepsia 2001 in press.

44. Naritoku DK, Hulihan J, Kamin M, Karim R, Olsen W. Reduction of AED co-therapy improves tolerability of add-on therapy with topiramate: a novel randomized study. Epilepsia 2001 in press.